Ruthenium(iii) complexes containing thiazole-based ligands that modulate amyloid-β aggregation.

Area of Science:

• Neuroscience
• Medicinal Chemistry
• Materials Science

Background:

• Alzheimer's Disease (AD) is characterized by amyloid-beta (Aβ) peptide aggregation.
• Soluble Aβ species, not just deposits, are neurotoxic.
• Metal-based therapeutics offer a unique approach to target soluble Aβ.

Purpose of the Study:

• To investigate structure-activity relationships (SAR) of Ruthenium(III) complexes for AD therapy.
• To synthesize and evaluate derivatives of NAMI-A and PMRU20 complexes.
• To understand how ligand modifications impact Aβ aggregation inhibition.

Main Methods:

• Synthesis of novel Ruthenium(III) complex derivatives.
• Thioflavin T fluorescence assays.
• Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) for Aβ aggregation analysis.

Main Results:

• Thiazole ligands significantly mitigate Aβ aggregation.
• Ligand functional groups influence activity: NH₂ > CH₃ > H.
• Metal center symmetry had minimal impact on therapeutic activity.

Conclusions:

• Ruthenium(III) complexes with specific thiazole ligands are effective against Aβ aggregation.
• Hydrogen-bonding interactions between ligands and Aβ are crucial for therapeutic efficacy.
• These findings guide the development of novel metallotherapeutics for Alzheimer's Disease.